Cargando…

Prevalence of QTc Prolongation in Patients with Parkinson’s Disease. Assessment of the Effects of Drugs, Clinical Risk Factors and Used Correction Formula

Background: Parkinson’s disease (PD) is a possible risk factor for corrected QT interval (QTc) prolongation. PD patients frequently take QTc-prolonging drugs. The aim of the study was to assess the prevalence of QTc prolongation in PD and the influence of drugs and other potential risk factors on th...

Descripción completa

Detalles Bibliográficos
Autores principales: Malkiewicz, Jakub J., Malkiewicz, Maciej, Siuda, Joanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037693/
https://www.ncbi.nlm.nih.gov/pubmed/33807236
http://dx.doi.org/10.3390/jcm10071396
_version_ 1783677203206111232
author Malkiewicz, Jakub J.
Malkiewicz, Maciej
Siuda, Joanna
author_facet Malkiewicz, Jakub J.
Malkiewicz, Maciej
Siuda, Joanna
author_sort Malkiewicz, Jakub J.
collection PubMed
description Background: Parkinson’s disease (PD) is a possible risk factor for corrected QT interval (QTc) prolongation. PD patients frequently take QTc-prolonging drugs. The aim of the study was to assess the prevalence of QTc prolongation in PD and the influence of drugs and other potential risk factors on the QTc length in PD. Methods: 101 patients with PD and a good quality ECG were included in the study. The prolonged QTc was defined as ≥450 ms for men and ≥460 ms for women. Bazett’s (QTcB) and Framingham (QTcF) formulas were utilized to calculate QTc. Data about sex, age, PD duration, disease’s severity, comorbidities and QTc-prolonging drugs were collected. Multiple linear regressions with backward elimination were used to assess factors influencing the QTc. Results: A long QTc was presented in 13 patients (12.9%) for QTcB and 4 patients (4%) for QTcF. Longer QTc in PD patients was associated with older age, male sex and QTc-prolonging drugs regardless of the used formula. The QTcB was also significantly affected by the heart rate (HR). Conclusion: QTc prolongation is common in PD. Age, drugs and male gender are potential risk factors for QTc prolongation in PD.
format Online
Article
Text
id pubmed-8037693
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80376932021-04-12 Prevalence of QTc Prolongation in Patients with Parkinson’s Disease. Assessment of the Effects of Drugs, Clinical Risk Factors and Used Correction Formula Malkiewicz, Jakub J. Malkiewicz, Maciej Siuda, Joanna J Clin Med Article Background: Parkinson’s disease (PD) is a possible risk factor for corrected QT interval (QTc) prolongation. PD patients frequently take QTc-prolonging drugs. The aim of the study was to assess the prevalence of QTc prolongation in PD and the influence of drugs and other potential risk factors on the QTc length in PD. Methods: 101 patients with PD and a good quality ECG were included in the study. The prolonged QTc was defined as ≥450 ms for men and ≥460 ms for women. Bazett’s (QTcB) and Framingham (QTcF) formulas were utilized to calculate QTc. Data about sex, age, PD duration, disease’s severity, comorbidities and QTc-prolonging drugs were collected. Multiple linear regressions with backward elimination were used to assess factors influencing the QTc. Results: A long QTc was presented in 13 patients (12.9%) for QTcB and 4 patients (4%) for QTcF. Longer QTc in PD patients was associated with older age, male sex and QTc-prolonging drugs regardless of the used formula. The QTcB was also significantly affected by the heart rate (HR). Conclusion: QTc prolongation is common in PD. Age, drugs and male gender are potential risk factors for QTc prolongation in PD. MDPI 2021-03-31 /pmc/articles/PMC8037693/ /pubmed/33807236 http://dx.doi.org/10.3390/jcm10071396 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Malkiewicz, Jakub J.
Malkiewicz, Maciej
Siuda, Joanna
Prevalence of QTc Prolongation in Patients with Parkinson’s Disease. Assessment of the Effects of Drugs, Clinical Risk Factors and Used Correction Formula
title Prevalence of QTc Prolongation in Patients with Parkinson’s Disease. Assessment of the Effects of Drugs, Clinical Risk Factors and Used Correction Formula
title_full Prevalence of QTc Prolongation in Patients with Parkinson’s Disease. Assessment of the Effects of Drugs, Clinical Risk Factors and Used Correction Formula
title_fullStr Prevalence of QTc Prolongation in Patients with Parkinson’s Disease. Assessment of the Effects of Drugs, Clinical Risk Factors and Used Correction Formula
title_full_unstemmed Prevalence of QTc Prolongation in Patients with Parkinson’s Disease. Assessment of the Effects of Drugs, Clinical Risk Factors and Used Correction Formula
title_short Prevalence of QTc Prolongation in Patients with Parkinson’s Disease. Assessment of the Effects of Drugs, Clinical Risk Factors and Used Correction Formula
title_sort prevalence of qtc prolongation in patients with parkinson’s disease. assessment of the effects of drugs, clinical risk factors and used correction formula
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037693/
https://www.ncbi.nlm.nih.gov/pubmed/33807236
http://dx.doi.org/10.3390/jcm10071396
work_keys_str_mv AT malkiewiczjakubj prevalenceofqtcprolongationinpatientswithparkinsonsdiseaseassessmentoftheeffectsofdrugsclinicalriskfactorsandusedcorrectionformula
AT malkiewiczmaciej prevalenceofqtcprolongationinpatientswithparkinsonsdiseaseassessmentoftheeffectsofdrugsclinicalriskfactorsandusedcorrectionformula
AT siudajoanna prevalenceofqtcprolongationinpatientswithparkinsonsdiseaseassessmentoftheeffectsofdrugsclinicalriskfactorsandusedcorrectionformula